Management of hypertension during Lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm.

Abstract

Hypertension (HTN) is the most frequent adverse event during treatment with Lenvatinib (LEN), but data on its best management are limited. To assess incidence, features and best management of LEN-related HTN in a consecutive single tertiary-care Centre cohort. 29 patients followed for a mean time of 29.8 months (6-77 months). After a mean follow-up of 6.8 months, HTN was recorded in 76% of cases, as a de novo occurrence in half of them. HTN significantly correlated with LEN dose, and was of grade 1, grade 2 and grade 3 in 5%, 50% and 45% of patients, respectively. The majority (77%) of patients with HTN developed proteinuria. There was no correlation between HTN and either proteinuria or clinical features or best morphological response or any other AE, with the exception of diarrhoea. Patients with or without pre-existing HTN or any other cardiovascular disease had a similar incidence of HTN during LEN, thus excluding the impact of this potential predisposing factor. After evaluation by a dedicated cardiologist, medical treatment was introduced in 21/22 patients (polytherapy in 20 of them). The most frequently used drugs were calcium channel blockers (CCB) due to their effect on vasodilation. In case of poor control, CCB were associated with one or more anti-hypertensive drug. HTN is a frequent and early adverse event in patients on LEN treatment. We suggest a diagnostic-therapeutic algorithm to be applied in clinical practice to allow efficient HTN control and improve patient compliance, reducing LEN discontinuation.